TOUR006 - 20 MG, TOUR006 - 50 MG — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Y
Phase 2 · Thyroid Eye Disease |
Tourmaline Bio, Inc., a Novartis C | TOUR006 - 20 MG, TOUR006 - 50 MG |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|